<DOC>
	<DOCNO>NCT00573755</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block blood flow tumor block enzyme need cell growth . Estrogen cause growth breast cancer cell . Aromatase inhibition therapy use letrozole , anastrozole , exemestane may fight breast cancer lower amount estrogen body make . It yet know whether sorafenib effective placebo give together letrozole , anastrozole , exemestane treat metastatic breast cancer . PURPOSE : This randomized phase II trial study well sorafenib work compare placebo give together letrozole , anastrozole , exemestane treat postmenopausal woman estrogen receptor-positive and/or progesterone receptor-positive metastatic breast cancer .</brief_summary>
	<brief_title>Sorafenib Letrozole , Anastrozole , Exemestane Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare progression-free survival postmenopausal woman estrogen receptor- and/or progesterone receptor-positive metastatic breast cancer treat sorafenib tosylate v placebo letrozole , anastrozole , exemestane . Secondary - To compare overall survival time treatment failure patient treat regimen . - To compare objective tumor response rate duration response patient treat regimen . - To assess adverse event profile sorafenib tosylate combination aromatase inhibitor patient . OUTLINE : This multicenter study . Patients stratify accord prior aromatase inhibitor therapy ( yes v ) line endocrine therapy metastatic disease ( first-line v second-line ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib tosylate twice daily oral letrozole , anastrozole , exemestane daily day 1-28 . - Arm II : Patients receive oral placebo twice daily oral letrozole , anastrozole , exemestane daily day 1-28 . In arm , treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Metastatic disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ( i.e. , MRI CT scan chest , abdomen pelvis ) ≥ 10 mm spiral CT scan Nonmeasurable disease allow , define lesion ( site disease ) , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) Must objective evidence progression within past 3 month No human epidermal growth factor receptor 2 ( HER2 ) /neu overexpression , define gene amplification fluorescence situ hybridization 3+ overexpression immunohistochemistry , unknown HER2/neu status No active brain metastasis Patients neurological symptom must undergo contrast CT scan MRI brain exclude active brain metastasis Patients treat brain metastasis allow provided evidence disease definitive therapy ( include steroid ) past 3 month Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive disease PATIENT CHARACTERISTICS : Female The Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Postmenopausal Hemoglobin ≥ 9.0 g/dL ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver involvement ) INR ≤ 1.5 PTT within normal limit Creatinine ≤ 1.5 time ULN Not nursing , pregnant , able become pregnant No significant traumatic injury within past 4 week No history bleed diathesis uncontrolled coagulopathy No serious , nonhealing wound , ulcer , bone fracture No clinically significant cardiac disease , include follow : New York Heart Association class IIIIV congestive heart failure Unstable angina ( i.e. , anginal symptom rest ) newonset angina ( i.e. , begin within past 3 month ) Myocardial infarction within past 6 month No cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension ( systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg ) , despite optimal medical management No thrombolic , embolic , venous , arterial event ( e.g. , cerebrovascular accident include transient ischemic attack ) within past 6 month No pulmonary hemorrhage bleed event &gt; grade 2 within past 4 week No hemorrhage bleed event ≥ grade 3 within past 4 week No active clinically serious infection &gt; grade 2 No know HIV infection No chronic hepatitis B C infection No previous concurrent cancer distinct primary site histology breast cancer except carcinoma situ cervix , treat basal cell skin cancer , superficial bladder tumor ( i.e. , Ta Tis ) , cancer curatively treat within past 5 year No know suspect allergy sorafenib tosylate agent use study PRIOR CONCURRENT THERAPY : See Disease Characteristics No major surgery open biopsy within past 4 week No 1 prior regimen endocrine therapy metastatic breast cancer , provide patient receive aromatase inhibitor within past 12 month No 1 prior regimen chemotherapy metastatic disease More 2 week since prior radiotherapy , except nontarget lesion singledose radiotherapy palliation Prior radiotherapy target lesion ( ) permit clear progression lesion since radiotherapy complete Concurrent anticoagulation treatment ( e.g. , warfarin heparin ) allow No concurrent Hypericum perforatum ( St. John 's wort ) , rifampin , bevacizumab , drug ( license investigational ) target vascular endothelial growth factor ( VEGF ) VEGF receptors No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>